What is 10x Genomics, Inc.'s impairment charges?

10x Genomics, Inc. (TXG) reported impairment charges of $313.25K in Q4 2025.

What does impairment charges mean?

Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.

10x Genomics, Inc. TXG Impairment Charges

Impairment Charges at other companies

RevvityRVTY

$1.2M-79.0%

Agilent TechnologiesA

$15M—

DanaherDHR

$0-100%

Other financials

Income statement

See full

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

See full

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

See full

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

See full

Market cap$4.41B+154%

Profitability

See full

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

See full

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCostsAndAssetImpairmentCharges.

The official record: 10x Genomics, Inc.’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 10x Genomics, Inc.'s impairment charges?: 10x Genomics, Inc. (TXG) reported impairment charges of $313.25K in Q4 2025.
What does impairment charges mean?: Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.